Publications in collaboration with researchers from Instituto de Investigación Sanitaria de Navarra (36)

2025

  1. DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy

    Journal of Thoracic Oncology, Vol. 20, Núm. 3, pp. 345-365

  2. Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program

    PLoS ONE, Vol. 20, Núm. 5 May

  3. ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer

    Molecular Medicine, Vol. 31, Núm. 1

2024

  1. Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism

    Translational Research, Vol. 269, pp. 1-13

  2. G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1

    Cell Death and Disease, Vol. 15, Núm. 11

  3. Lung Cancer Screening in People With COPD: The Pamplona-IELCAP Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 95-100

  4. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment

    Archivos de Bronconeumologia, Vol. 60, pp. S67-S76

  5. Ultrasensitive immunosensor for multiplex detection of cancer biomarkers carcinoembryonic antigen (CEA) and yamaguchi sarcoma viral oncogene homolog 1 (YES1) based on eco-friendly synthesized gold nanoparticles

    Talanta, Vol. 266

  6. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

    Cancers, Vol. 15, Núm. 12

  2. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  4. Development of electrochemical immunosensor for quantitative detection of non-small cell lung cancer (NSCLC) biomaker YES1

    Biosensors and Bioelectronics: X, Vol. 14

  5. Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

    Clinical cancer research : an official journal of the American Association for Cancer Research

  6. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  3. Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System

    Cancers, Vol. 14, Núm. 11

  4. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8

  5. Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer

    Advanced Science, Vol. 9, Núm. 26